Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.46 |
| ▸ | CNR2 | P34972 | 9/20 | 0.46 |
| ▸ | CBFB | Q13951 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653369 | 0.90 | CBFB (0.44) | CNR1CNR2CBFBEGLN1HCRTR1 | |
| SCHEMBL5649030 | 0.90 | CBFB (0.43) | CNR1CNR2CBFBEGLN1HCRTR1 | |
| SCHEMBL5652225 | 0.89 | METAP2 (0.43) | CNR1CNR2CBFBEGLN1METAP2 | |
| SCHEMBL5652546 | 0.87 | CNR1 (0.42) | CNR1CNR2CBFBEGLN1 | |
| SCHEMBL5651303 | 0.86 | CBFB (0.47) | CNR1CNR2CBFBEGLN1HCRTR1 | |
| SCHEMBL5649813 | 0.85 | HDAC6 (0.45) | CNR1CNR2HCRTR1HCRTR2 | |
| SCHEMBL5650683 | 0.81 | RHEB (0.47) | CNR1CNR2 | |
| SCHEMBL5651035 | 0.80 | PRSS12 (0.42) | CNR1CNR2 | |
| SCHEMBL5650808 | 0.80 | MGAM (0.48) | CNR2 | |
| SCHEMBL5650474 | 0.79 | CNR1 (0.41) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | CNR1 68/4885CNR2 129/4885CBFB 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.